Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | CDC25B | P30305 | 5/20 | 0.46 |
| ▸ | ACP1 | P24666 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372136 | 0.77 | PTPN1 (0.50) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL70825 | 0.73 | PTPN1 (0.56) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL10997593 | 0.73 | HSD11B1 (0.38) | PTPN1CDC25BACP1ALDH1A1KDM4E | |
| SCHEMBL1356857 | 0.71 | PTPN1 (0.62) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL7114676 | 0.68 | PTPN1 (0.74) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL13403500 | 0.67 | PTPN1 (0.59) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL8194669 | 0.67 | PTPN1 (0.59) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL13759854 | 0.67 | PTPN1 (0.48) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL10996134 | 0.67 | HSD11B1 (0.36) | PTPN1CDC25BACP1ALDH1A1L3MBTL1 | |
| SCHEMBL9730908 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4547516-A | Antisecretory agents derived from meldrum's acid | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-10-15 | — | — | US | claimed |
| EP-2385948-B1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LTD (IN) | 2017-10-04 | — | — | EP | disclosed |
| US-8822484-B2 | Fused thiazolo and oxazolo pyrimidinones | TORRENT PHARMACEUTICALS LIMITED (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20130331406-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2013-12-12 | — | — | US | disclosed |
| US-8541430-B2 | Fused thiazolo and oxazolo pyrimidinones | TORRENT PHARMACEUTICALS LIMITED (IN) | 2013-09-24 | — | — | US | disclosed |
| EP-2385948-A1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | Torrent Pharmaceuticals Limited (IN) | 2011-11-16 | — | — | EP | disclosed |
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| WO-2011045811-A1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331406-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, TYMS, UGT1A8 | PTPN1 2323/4885CDC25B 2570/4885ACP1 4334/4885 |
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, ABCG2, TALDO1 | PTPN1 1474/4885CDC25B 2313/4885ACP1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.